In this article
Cholera Vaccine and Colorectal Cancer Survival
A Swedish study showed that vaccination with cholera after diagnosis of colorectal cancer can reduce the risk of colorectal cancer-related death and all-cause mortality. (Online version of Gastroenterology September 15, 2017).
This should be the first national population-based study to explore the relationship between vaccination with cholera after diagnosis of colorectal cancer and the risk of death. Previous studies have shown that the cholera vaccine may have multiple effects in regulating the body’s immune system and may also reduce the formation of colon polyps in mouse models.
The researchers believe that colorectal cancer is more common in developed countries than in developing countries. Perhaps less exposure to microbes in childhood is also associated with an increased risk of developing colorectal cancer in adulthood.
Study Analysis and Mortality Reduction
The researchers used the Swedish National Cancer Registration and Prescription Drug Registration Database to retrospectively analyze the data of 175 patients who received cholera vaccine after diagnosis of colorectal cancer from mid-2005 to 2012. As for the reason why the cholera vaccine is unknown, it may be that patients need to travel to other countries.
The analysis showed that compared with patients who were not vaccinated with cholera (525 patients), patients who received cholera vaccine after diagnosis of colorectal cancer had a 47% lower risk of colorectal cancer death and a 41% overall risk of death. This survival advantage exists in patients with different ages, genders, and stages of colorectal cancer at diagnosis.
Immune System Stimulation and Hypotheses
The researchers hypothesized that the cholera vaccine may play a role in inhibiting the progression of colorectal cancer by stimulating immune cells such as CD8 positive T cells, macrophages and NK cells, and / or by affecting the expression of genes related to tumorigenesis. The researchers believe that if the results of these studies can be verified in other population-based studies or randomized clinical studies, then the use of cholera vaccine for adjuvant treatment of colorectal cancer is not impossible.
Researchers studying microbial infections and tumors have pointed out that more and more research evidence supports that microbes or their products can stimulate the body’s immune system and bring health benefits for the protection of certain types of tumors and immune-related diseases However, the improvement of sanitary conditions makes us less and less likely to obtain a healthy immune system caused by microbial exposure. A safe oral vaccine that can enhance immune function may bring us significant health benefits.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.